Microvascular abnormalities (MVAs) by arm of study and expert adjudication of relatedness of visual acuity loss
| B ASELINE | Monotherapy ( N = 80 ) | 16 Gy ( N = 75 ) | 24 Gy ( N = 75 ) |
| MVA called by reading centre | 0 | 1 | 1 |
| MVA confirmed by independent experts | 0 | 0 | 0 |
| YEAR 1 | Monotherapy (N=79) | 16 Gy (N=74) | 24 Gy (N=72) |
| MVA called by reading centre | 1 | 2 | 4 |
| MVA confirmed by independent experts | 0 | 0 | 0 |
| Vision loss associated with RT | 0 | 0 | 0 |
| YEAR 2 | Monotherapy (N=73) | 16 Gy (N=69) | 24 Gy (N=68) |
| MVA called by reading centre | 6 | 11 | 13 |
| MVA confirmed by independent experts | 0 | 9 | 9 |
| Vision loss associated with RT | 0 | 0 | 2 |
| YEAR 3 | Monotherapy (N=67) | 16 Gy (N=58) | 24 Gy (N=64) |
| MVA called by reading centre | 1 | 22 | 19 |
| MVA confirmed by independent experts | 0 | 19 | 18 |
| Eyes with MVA regression | 0 | 3 | 6 |
| Vision loss associated with SRT | 0 | 4 | 1 |
Table 3 the accrual of microvascular abnormalities (MVA) by year. The frequency of MVA from the reading centre grading and that after expert consensus adjudication are shown. The number of eyes with VA loss possibly attributable to MVA in the opinion of the experts is also shown.
MVA, microvascular abnormality; Gy gray; SRT, stereotactic radiotherapy.